BCI
SUPN icon

Brinker Capital Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Brinker Capital Investments’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$910K Buy
19,564
+4,602
+31% +$221K 0.01% 1208
2026
Q1 		$773K Buy
14,962
+3,307
+28% +$168K 0.01% 1257
2025
Q4 		$579K Sell
11,655
-677
-5% -$32.9K ﹤0.01% 1534
2025
Q3 		$589K Sell
12,332
-209
-2% -$8.42K ﹤0.01% 1485
2025
Q2 		$395K Sell
12,541
-235
-2% -$7.53K ﹤0.01% 1588
2025
Q1 		$418K Buy
+12,776
New +$453K ﹤0.01% 1490

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Brinker Capital Investments's SUPN Position: Q2 2026 in Review

Brinker Capital Investments increased its Supernus Pharmaceuticals (SUPN) stake by 31% in Q2 2026, buying an estimated $221K and bringing the position to 19,564 shares worth $910K. The position accounts for 0.01% of the portfolio, ranked #1208.

Brinker Capital Investments first reported a position in SUPN in Q1 2025 and has held it in 6 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Brinker Capital Investments held 19,564 shares of Supernus Pharmaceuticals worth $910K as of Q2 2026.
  • Brinker Capital Investments bought 4,602 Supernus Pharmaceuticals shares in Q2 2026, an estimated $221K.
  • Supernus Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1208 holding.
  • Brinker Capital Investments first reported a position in Supernus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.